Heart Failure News and Research

RSS

Heart failure (HF) is a condition in which a problem with the structure or function of the heart impairs its ability to supply sufficient blood flow to meet the body's needs. It should not be confused with cardiac arrest or myocardial infarction.

Further analysis from ATHENA study showed Multaq (Dronedarone) reduced risk of stroke in patients with atrial fibrillation

The results of a post-hoc analysis of the data from the ATHENA study were presented today at the clinical trial update session of the European Society of Cardiology congress 2008, in Munich, Germany.

3 Sep 2008

Results from the Simvastatin and Ezetimibe in aortic stenosis study

The SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) study has investigated the effects of intensive cholesterol lowering with the combination of simvastatin (40 mg daily) and ezetimibe (10 mg daily) in patients with aortic stenosis.

2 Sep 2008

European guidelines for acute pulmonary embolism

Acute pulmonary embolism (PE) is a relatively common cardiovascular emergency. Clots originating in the leg veins may become detached and obstruct the lung vessels. This obstruction may lead to a rise of pressure in the pulmonary circulation and possibly to life-threatening heart failure.

2 Sep 2008

New guidelines on heart failure

Heart failure is a leading cause of death and hospitalisation and represents a major burden on health services. It is estimated that over 15 million people in Europe suffer from heart failure and the syndrome accounts for over 2% of national expenditure on health. The new guidelines on heart failure from the European Society of Cardiology are eagerly awaited.

2 Sep 2008

New diagnostic tools and biomarkers

Patients presenting shortness of breath on arrival at the emergency department (ED) can gain from improved diagnosis allowing physicians to distinguish congestive heart failure patients from those presenting pneumonia.

1 Sep 2008

Faster heart rate linked to increased heart attack risk

A long-term study has revealed a link between a faster heart rate and the risk of a heart attack and the researchers say that heart disease patients with a pulse of more than 70 beats a minute are most at risk.

1 Sep 2008

DES in diabetic patients

The issue of using or not using DES in patients with diabetes will be debated between Professor Wijns, who discourages DES and Professor Silber, who feels that they should be used.

31 Aug 2008

TIME-CHF Trial: Elderly HF patients do not benefit from intensive medical therapy

Intensified, BNP-guided therapy was no more effective than a standard, symptom-guided approach in elderly heart failure patients in reducing the number of deaths and all-cause hospitalisations. However, the response to this intervention differed significantly between patients aged 60-74 years and those aged ¡Ý75 years. This indicates the need for specific data in this large subset of very old heart failure patients who have been largely excluded from large treatment trials.

31 Aug 2008

The BEAUTIFUL study: Ivabradine and the reduction of cardiovascular events

The results of the much awaited BEAUTIFUL (morBidity-mortality EvAlUaTion of the If inhibitor ivabradine in patients with CAD and left ventricULar dysfunction) trial have shown that coronary artery disease (CAD) patients with left ventricular dysfunction (LVD) and a heart rate more than 70 bpm have a significantly higher risk of cardiovascular death and other cardiovascular events and in these patients (heart rate above 70 bpm) treatment with ivabradine further reduces the risk of the most important coronary events such as fatal and non-fatal myocardial infarction and coronary revascularisation by one third, even when these patients are already receiving optimal therapy.

31 Aug 2008

The GISSI-HF trial: Effects of n-3 PUFA in 6,975 patients with symptomatic chronic heart failure

Researchers involved in the GISSI trial, concluded that simple, safe and cheap treatment with n-3 PUFA can provide a moderate beneficial advantage in terms of mortality and admission to hospital for cardiovascular reasons in patients with chronic heart failure, in a context of usual care.

31 Aug 2008

Global study shows Telmisartan reduces outcome of cardiovascular death, heart attack or stroke

An international study led by Canadian researchers has found that telmisartan, a medication used to lower blood pressure, reduced the outcome of cardiovascular death, heart attack or stroke in people who are unable to tolerate a widely available and effective standard treatment.

31 Aug 2008

Computed tomography provides anatomy - we need ischemia!

Cardiac computed tomography has revolutionized cardiac imaging in recent years by providing exquisitely detailed cardiac anatomy, including, but not limited to, coronary anatomy.

31 Aug 2008

New molecular imaging techniques aim at detection of earliest steps of disease development

An emerging discipline of noninvasive cardiac imaging, molecular imaging, has evolved constantly in the last few years and is increasingly being translated from the preclinical to the clinical level.

31 Aug 2008

Researchers devise means to create blood by discovering earliest form of human blood stem cells

Johns Hopkins researchers have discovered the earliest form of human blood stem cells and deciphered the mechanism by which these embryonic stem cells replicate and grow. They also found a surprising biological marker that pinpoints these stem cells, which serve as the progenitors for red blood cells and lymphocytes.

28 Aug 2008

Thiazolidinediones - diabetes drugs carry significant cardiovascular risks

A class of oral drugs used to treat type 2 diabetes may significantly increase the risk of serious cardiovascular events, according to an editorial published online in Heart Wednesday by two Wake Forest University School of Medicine faculty members.

28 Aug 2008

Gleevec receives FDA priority review for gastrointestinal stromal tumors after surgery

Novartis has announced that Gleevec (imatinib mesylate) tablets, (known as Glivec (imatinib) outside the US, Canada and Israel), has been granted priority review status by the US Food and Drug Administration (FDA) as the first therapy to be reviewed for use after surgery in kit-positive gastrointestinal stromal tumors (GIST).

27 Aug 2008